Robust Phase I trial growth across Asia Pacific

13 February 2023

Contract research organization (CRO) Novotech has published a new global report on Phase I trial activity including current metrics on fast growth regions and therapeutic areas.

The data analysis found that Asia Pacific has been the fastest-growing region for Phase I trials in the last 10 years, reaching a share of 58% in 2022, with China leading the Phase I trials globally.

According to the report, titled "Phase I Global Clinical Trial Landscape - Focus on Asia Pacific," in 2022 Asia Pacific accounted for a 58% share of the approximately 3,600 Phase I trials initiated globally in 2022. The report found that Asia Pacific has been the fastest growing region for Phase I trials in the last 10 years with a 10-yeay compound annual growth rate (CAGR) of 18%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK